Ignite Creation Date:
2025-12-24 @ 7:35 PM
Ignite Modification Date:
2025-12-30 @ 9:19 AM
Study NCT ID:
NCT00377403
Status:
COMPLETED
Last Update Posted:
2012-12-28
First Post:
2006-09-14
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Treatment of Acute Sinusitis
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000096825', 'term': 'Rhinosinusitis'}, {'id': 'D012852', 'term': 'Sinusitis'}], 'ancestors': [{'id': 'D012220', 'term': 'Rhinitis'}, {'id': 'D012141', 'term': 'Respiratory Tract Infections'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D010254', 'term': 'Paranasal Sinus Diseases'}, {'id': 'D009668', 'term': 'Nose Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D010038', 'term': 'Otorhinolaryngologic Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000082', 'term': 'Acetaminophen'}, {'id': 'D000658', 'term': 'Amoxicillin'}, {'id': 'D003915', 'term': 'Dextromethorphan'}, {'id': 'D006140', 'term': 'Guaifenesin'}, {'id': 'D000111', 'term': 'Acetylcysteine'}, {'id': 'D054199', 'term': 'Pseudoephedrine'}], 'ancestors': [{'id': 'D000083', 'term': 'Acetanilides'}, {'id': 'D000813', 'term': 'Anilides'}, {'id': 'D000577', 'term': 'Amides'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D000814', 'term': 'Aniline Compounds'}, {'id': 'D000588', 'term': 'Amines'}, {'id': 'D000667', 'term': 'Ampicillin'}, {'id': 'D010400', 'term': 'Penicillin G'}, {'id': 'D010406', 'term': 'Penicillins'}, {'id': 'D047090', 'term': 'beta-Lactams'}, {'id': 'D007769', 'term': 'Lactams'}, {'id': 'D013457', 'term': 'Sulfur Compounds'}, {'id': 'D006574', 'term': 'Heterocyclic Compounds, 2-Ring'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D009019', 'term': 'Morphinans'}, {'id': 'D053610', 'term': 'Opiate Alkaloids'}, {'id': 'D000470', 'term': 'Alkaloids'}, {'id': 'D006572', 'term': 'Heterocyclic Compounds, Bridged-Ring'}, {'id': 'D006576', 'term': 'Heterocyclic Compounds, 4 or More Rings'}, {'id': 'D010616', 'term': 'Phenanthrenes'}, {'id': 'D011084', 'term': 'Polycyclic Aromatic Hydrocarbons'}, {'id': 'D011083', 'term': 'Polycyclic Compounds'}, {'id': 'D006139', 'term': 'Guaiacol'}, {'id': 'D008738', 'term': 'Methyl Ethers'}, {'id': 'D004987', 'term': 'Ethers'}, {'id': 'D010647', 'term': 'Phenyl Ethers'}, {'id': 'D002396', 'term': 'Catechols'}, {'id': 'D010636', 'term': 'Phenols'}, {'id': 'D001555', 'term': 'Benzene Derivatives'}, {'id': 'D006841', 'term': 'Hydrocarbons, Aromatic'}, {'id': 'D006844', 'term': 'Hydrocarbons, Cyclic'}, {'id': 'D006838', 'term': 'Hydrocarbons'}, {'id': 'D003545', 'term': 'Cysteine'}, {'id': 'D000603', 'term': 'Amino Acids, Sulfur'}, {'id': 'D000596', 'term': 'Amino Acids'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}, {'id': 'D011412', 'term': 'Propanolamines'}, {'id': 'D000605', 'term': 'Amino Alcohols'}, {'id': 'D000438', 'term': 'Alcohols'}, {'id': 'D020005', 'term': 'Propanols'}, {'id': 'D010627', 'term': 'Phenethylamines'}, {'id': 'D005021', 'term': 'Ethylamines'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'jgarbutt@dom.wustl.edu', 'phone': '314-454-8613', 'title': 'Jane Garbut,MD', 'organization': 'Washington University in St Louis'}, 'certainAgreement': {'piSponsorEmployee': False, 'restrictiveAgreement': False}}, 'adverseEventsModule': {'eventGroups': [{'id': 'EG000', 'title': 'Intervention Arm', 'description': 'Amoxicillin 500mg tid for 10 days in addition to symptomatic treatments', 'otherNumAtRisk': 85, 'otherNumAffected': 39, 'seriousNumAtRisk': 85, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Symptomatic Treatments Only', 'description': 'Placebo for 10 days in addition to symptomatic treatments', 'otherNumAtRisk': 81, 'otherNumAffected': 36, 'seriousNumAtRisk': 81, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'Other non-serious adverse events', 'stats': [{'groupId': 'EG000', 'numAtRisk': 85, 'numEvents': 39, 'numAffected': 39}, {'groupId': 'EG001', 'numAtRisk': 81, 'numEvents': 36, 'numAffected': 36}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT'}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'SNOT-16 Score (Sino-Nasal Outcomes Test) at Day 3', 'denoms': [{'units': 'Participants', 'counts': [{'value': '81', 'groupId': 'OG000'}, {'value': '74', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Intervention Arm', 'description': 'Amoxicillin 500mg tid for 10 days in addition to symptomatic treatments'}, {'id': 'OG001', 'title': 'Symptomatic Treatments Only', 'description': 'Placebo for 10 days in addition to symptomatic treatments'}], 'classes': [{'categories': [{'measurements': [{'value': '1.12', 'spread': '0.54', 'groupId': 'OG000'}, {'value': '1.14', 'spread': '0.55', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.83', 'groupIds': ['OG000', 'OG001'], 'ciPctValue': '95', 'pValueComment': 'The a priori threshold for statistical significnace was p less than or equal to 0.05', 'groupDescription': 'We used analysis of variance, controlling for disease severity at baseline to test the null hypothesis that there was no difference between study groups at this point in time.', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted for disease severity at baseline', 'testedNonInferiority': False}], 'paramType': 'MEAN', 'timeFrame': '4 days', 'description': 'The Sino-Nasal Outcomes Test (SNOT-16) assesses disease-specific quality of life for acute and chronic rhinosinusitis. This brief instrument assesses 16 sinus-related symptoms and was administered by phone. The respondent reported how much they were bothered by each item considering both its severity and frequency. Response options include no problem (0), mild or slight problem (1), moderate problem (2), severe problem (3). The SNOT-16 score is the mean score from all 16 items and ranges from 0 (minimal impact) to 3 (significant impact).', 'unitOfMeasure': 'Units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'We analysed all participants for whom we had data at Day 3. We were unable to complete the telephone interview with 11 subjects.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Intervention Arm', 'description': 'Amoxicillin 500mg tid for 10 days in addition to symptomatic treatments'}, {'id': 'FG001', 'title': 'Symptomatic Treatments Only', 'description': 'Placebo for 10 days in addition to symptomatic treatments'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '85'}, {'groupId': 'FG001', 'numSubjects': '81'}]}, {'type': 'Day -3 Assessment', 'achievements': [{'groupId': 'FG000', 'numSubjects': '81'}, {'groupId': 'FG001', 'numSubjects': '74'}]}, {'type': 'Day 7 Assessment', 'achievements': [{'groupId': 'FG000', 'numSubjects': '80'}, {'groupId': 'FG001', 'numSubjects': '75'}]}, {'type': 'Day 10 Assessment', 'achievements': [{'groupId': 'FG000', 'numSubjects': '81'}, {'groupId': 'FG001', 'numSubjects': '71'}]}, {'type': 'Day 28 Assessment', 'achievements': [{'groupId': 'FG000', 'numSubjects': '82'}, {'groupId': 'FG001', 'numSubjects': '77'}]}, {'type': 'COMPLETED', 'achievements': [{'comment': 'The number varied by day of follow-up from 80 to 82 in the intervention group.', 'groupId': 'FG000', 'numSubjects': '81'}, {'comment': 'The number varied by day of follow-up from 71 to 77 in the symptomatic treatment only group.', 'groupId': 'FG001', 'numSubjects': '74'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '4'}, {'groupId': 'FG001', 'numSubjects': '7'}]}], 'dropWithdraws': [{'type': 'Unable to contact for telephone intervie', 'reasons': [{'groupId': 'FG000', 'numSubjects': '4'}, {'groupId': 'FG001', 'numSubjects': '7'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '85', 'groupId': 'BG000'}, {'value': '81', 'groupId': 'BG001'}, {'value': '166', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'Intervention Arm', 'description': 'Amoxicillin 500mg tid for 10 days in addition to symptomatic treatments'}, {'id': 'BG001', 'title': 'Symptomatic Treatments Only', 'description': 'Placebo for 10 days in addition to symptomatic treatments'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age Continuous', 'classes': [{'categories': [{'measurements': [{'value': '32', 'groupId': 'BG000', 'lowerLimit': '18', 'upperLimit': '69'}, {'value': '31', 'groupId': 'BG001', 'lowerLimit': '18', 'upperLimit': '66'}, {'value': '32', 'groupId': 'BG002', 'lowerLimit': '18', 'upperLimit': '69'}]}]}], 'paramType': 'MEDIAN', 'unitOfMeasure': 'years', 'dispersionType': 'FULL_RANGE'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '54', 'groupId': 'BG000'}, {'value': '52', 'groupId': 'BG001'}, {'value': '106', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '31', 'groupId': 'BG000'}, {'value': '29', 'groupId': 'BG001'}, {'value': '60', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE4'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 172}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2006-10'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2012-12', 'completionDateStruct': {'date': '2010-08', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2012-12-24', 'studyFirstSubmitDate': '2006-09-14', 'resultsFirstSubmitDate': '2011-03-31', 'studyFirstSubmitQcDate': '2006-09-14', 'lastUpdatePostDateStruct': {'date': '2012-12-28', 'type': 'ESTIMATED'}, 'resultsFirstSubmitQcDate': '2011-06-03', 'studyFirstPostDateStruct': {'date': '2006-09-18', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2011-06-29', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2009-05', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'SNOT-16 Score (Sino-Nasal Outcomes Test) at Day 3', 'timeFrame': '4 days', 'description': 'The Sino-Nasal Outcomes Test (SNOT-16) assesses disease-specific quality of life for acute and chronic rhinosinusitis. This brief instrument assesses 16 sinus-related symptoms and was administered by phone. The respondent reported how much they were bothered by each item considering both its severity and frequency. Response options include no problem (0), mild or slight problem (1), moderate problem (2), severe problem (3). The SNOT-16 score is the mean score from all 16 items and ranges from 0 (minimal impact) to 3 (significant impact).'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['rhinosinusitis, sinusitis, amoxicillin'], 'conditions': ['Acute Respiratory Infections', 'Acute Rhinosinusitis']}, 'referencesModule': {'references': [{'pmid': '22337680', 'type': 'DERIVED', 'citation': 'Garbutt JM, Banister C, Spitznagel E, Piccirillo JF. Amoxicillin for acute rhinosinusitis: a randomized controlled trial. JAMA. 2012 Feb 15;307(7):685-92. doi: 10.1001/jama.2012.138.'}, {'pmid': '21844413', 'type': 'DERIVED', 'citation': 'Garbutt J, Spitznagel E, Piccirillo J. Use of the modified SNOT-16 in primary care patients with clinically diagnosed acute rhinosinusitis. Arch Otolaryngol Head Neck Surg. 2011 Aug;137(8):792-7. doi: 10.1001/archoto.2011.120.'}]}, 'descriptionModule': {'briefSummary': 'This study will compare the symptom relief provided by 5 cold medicines versus the symptom relief provided by the same 5 cold medicines plus the antibiotic, amoxicillin, in people who have sinus infections. Treatment with amoxicillin may be more effective than treatment with cold medicines alone. Two hundred adult volunteers, aged 18 to 70 years old, with sinus infections will participate in this study for 28 days. Volunteers will receive a 10-day course of either amoxicillin or placebo (substance containing no medication). In addition, all volunteers will receive pain medication, a chest decongestant, nasal decongestants, and cough medicine as needed. Volunteers will be interviewed by telephone on days 0, 3, 7, 10, and 28 following the start of treatment. The study will look at quality of life factors such as change in functional status (ability to perform daily activities) and symptoms, recurrence of the infection, satisfaction with care, and the direct costs of treatment.', 'detailedDescription': 'The primary objective of this phase IV, randomized, placebo controlled clinical trial is to determine the incremental effect of amoxicillin treatment compared with symptomatic treatments on disease-related quality of life in adults with clinically diagnosed acute bacterial rhinosinusitis. The secondary objective is to determine the incremental effect of amoxicillin treatment compared with symptomatic treatments on functional status, symptoms, disease recurrence, satisfaction with treatment, and direct costs of treatment in adults with clinically diagnosed acute bacterial rhinosinusitis. The tertiary objective is to identify prognostic indicators for clinical improvement with antibiotic treatment in adults with clinically diagnosed acute bacterial rhinosinusitis. Two hundred adult subjects, 18 to 70 years old, who meet the recommended criteria for acute bacterial rhinosinusitis, will be enrolled from 8 practice sites. Subjects will be randomized to receive a 10-day course of either amoxicillin or placebo. In addition, all subjects will receive an analgesic, an oral decongestant, a nasal saline spray, and an antitussive agent. Subject outcomes will be assessed by telephone interview at 0, 3, 7, 10, and 28 days. The primary outcome is the disease-specific quality of life at Day 3 measured with the SNOT-16, a validated evaluative instrument. Secondary outcomes include change in functional status and symptoms, disease recurrence, satisfaction with care and the direct costs of treatment. Tertiary outcome measures include possible subject and disease-related factors that predict clinical improvement with antibiotic treatment at Day 3 for use in future studies to aid clinical decision-making.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '70 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. The subject must be male or female, and between the ages of 18 and 70 years old.\n2. The subject must have symptoms of acute bacterial rhinosinusitis.\n3. The subject must be attending a participating primary care practice in the community.\n4. The subject must have symptoms of acute bacterial rhinosinusitis self-assessed as moderate, severe, or very severe.\n5. The subject must have access to a phone.\n\nExclusion Criteria:\n\n1. The subject is less than 18 years old or more than 70 years old.\n2. The subject has very mild or mild symptom severity assessed by self report.\n3. The subject has an allergy to penicillin or amoxicillin.\n4. The subject has received antibiotic therapy within the past 4 weeks (including chronic treatment for acne and low dose prophylactic treatment).\n5. The subject has complications of sinusitis (facial edema, cellulitis, or orbital, meningeal or cerebral signs).\n6. The subject is thought to require intravenous antibiotics or hospital admission.\n7. The subject is pregnant. (This will be assessed by self-report. A pregnancy test will not be required).\n8. The subject has a comorbidity that may impair their immune response (such as immunodeficiency disease, uncontrolled cancer, or chemotherapy or radiation treatment).\n9. The subject has cystic fibrosis.\n10. The subject has Type I diabetes or is taking insulin to treat diabetes.\n11. The subject had prior sinus surgery.\n12. The subject requires an antibiotic for a concurrent condition such as an ear infection.\n13. The subject is not able to complete the study protocol because of language barriers, lack of telephone access, or other issues.\n14. Any other condition that the provider feels may interfere with the study.'}, 'identificationModule': {'nctId': 'NCT00377403', 'briefTitle': 'Treatment of Acute Sinusitis', 'organization': {'class': 'OTHER', 'fullName': 'Washington University School of Medicine'}, 'officialTitle': 'Randomized Clinical Trial to Evaluate Guidelines for Acute Rhinosinusitis (Phase IV Study)', 'orgStudyIdInfo': {'id': '05-0140'}, 'secondaryIdInfos': [{'id': 'U01AI064655-01A1', 'link': 'https://reporter.nih.gov/quickSearch/U01AI064655-01A1', 'type': 'NIH'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Intervention Arm', 'description': 'Amoxicillin 500mg three times a day (tid) for 10 days in addition to symptomatic treatments', 'interventionNames': ['Drug: Acetaminophen', 'Drug: Amoxicillin', 'Drug: Dextromethorphan hydrobromide with guaifenesin', 'Drug: Guaifenesin', 'Drug: Pseudoephedrine Sustained Action', 'Drug: Saline spray (0.65%)']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Symptomatic treatments only', 'description': 'Placebo for 10 days in addition to symptomatic treatments', 'interventionNames': ['Drug: Acetaminophen', 'Drug: Dextromethorphan hydrobromide with guaifenesin', 'Drug: Guaifenesin', 'Drug: Pseudoephedrine Sustained Action', 'Drug: Saline spray (0.65%)']}], 'interventions': [{'name': 'Acetaminophen', 'type': 'DRUG', 'otherNames': ['Tylenol'], 'description': 'Symptomatic treatment:\n\nDose: 500mg every 4 to 6 hours for pain or fever', 'armGroupLabels': ['Intervention Arm', 'Symptomatic treatments only']}, {'name': 'Amoxicillin', 'type': 'DRUG', 'otherNames': ['Amoxil'], 'description': 'Intervention drug:\n\nDose: 500mg tid for 10 days', 'armGroupLabels': ['Intervention Arm']}, {'name': 'Dextromethorphan hydrobromide with guaifenesin', 'type': 'DRUG', 'otherNames': ['Robitussin'], 'description': 'Symptomatic treatment:\n\nDose: 10mls every 4 to 6 hours for cough', 'armGroupLabels': ['Intervention Arm', 'Symptomatic treatments only']}, {'name': 'Guaifenesin', 'type': 'DRUG', 'otherNames': ['Mucinex OTC'], 'description': 'Symptomatic treatment:\n\nDose: 600mg every 12 hours to thin secretions', 'armGroupLabels': ['Intervention Arm', 'Symptomatic treatments only']}, {'name': 'Pseudoephedrine Sustained Action', 'type': 'DRUG', 'otherNames': ['Sudafed'], 'description': 'Symptomatic treatment:\n\nDose: 120mg every 12 hours for nasal congestion', 'armGroupLabels': ['Intervention Arm', 'Symptomatic treatments only']}, {'name': 'Saline spray (0.65%)', 'type': 'DRUG', 'otherNames': ['Ocean Nasal Spray'], 'description': 'Symptomatic treatment:\n\nDose: 2 squeezes per nostril as needed for nasal congestion', 'armGroupLabels': ['Intervention Arm', 'Symptomatic treatments only']}]}, 'contactsLocationsModule': {'locations': [{'zip': '63110', 'city': 'St Louis', 'state': 'Missouri', 'country': 'United States', 'facility': 'Washington University in St. Louis', 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}}], 'overallOfficials': [{'name': 'Jane Garbutt, MB, ChB', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Washington University School of Medicine'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Washington University School of Medicine', 'class': 'OTHER'}, 'collaborators': [{'name': 'National Institute of Allergy and Infectious Diseases (NIAID)', 'class': 'NIH'}], 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Associate Professor', 'investigatorFullName': 'Jane Garbutt, MD', 'investigatorAffiliation': 'Washington University School of Medicine'}}}}